IL161003A0 - Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity - Google Patents

Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity

Info

Publication number
IL161003A0
IL161003A0 IL16100302A IL16100302A IL161003A0 IL 161003 A0 IL161003 A0 IL 161003A0 IL 16100302 A IL16100302 A IL 16100302A IL 16100302 A IL16100302 A IL 16100302A IL 161003 A0 IL161003 A0 IL 161003A0
Authority
IL
Israel
Prior art keywords
activity
methods
pharmaceutical compositions
cell adhesion
dopaminergic modulation
Prior art date
Application number
IL16100302A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL161003A0 publication Critical patent/IL161003A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16100302A 2001-10-29 2002-10-29 Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity IL161003A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33069201P 2001-10-29 2001-10-29
PCT/IL2002/000870 WO2003037247A2 (fr) 2001-10-29 2002-10-29 Procedes et compositions pharmaceutiques de modulation dopaminergique de l'adherence et de l'activite de cellules t

Publications (1)

Publication Number Publication Date
IL161003A0 true IL161003A0 (en) 2004-08-31

Family

ID=23290887

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16100302A IL161003A0 (en) 2001-10-29 2002-10-29 Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity

Country Status (5)

Country Link
US (1) US20050163773A1 (fr)
EP (1) EP1492565A4 (fr)
AU (1) AU2002347573A1 (fr)
IL (1) IL161003A0 (fr)
WO (1) WO2003037247A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
US7332597B2 (en) 2004-06-28 2008-02-19 University Of Kentucky Research Foundation Primers and probe to identify mycobacterium tuberculosis complex
AU2015201106B2 (en) * 2005-01-20 2016-09-29 Ampio Pharmaceuticals, Inc. Methylphenidate derivatives and uses of them
NZ556456A (en) 2005-01-20 2010-12-24 Inst Molecular Medicine Inc Methylphenidate derivatives and uses of them
US8691853B2 (en) * 2007-03-14 2014-04-08 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP2422769A1 (fr) * 2010-08-17 2012-02-29 Novaliq GmbH Compositions et procédés pour préservation et acceptation améliorées de greffe d'organe
CL2016000753A1 (es) * 2016-03-31 2017-11-10 Fund Ciencia Para La Vida Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.
WO2019145956A1 (fr) 2018-01-25 2019-08-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procédés d'immunothérapie améliorée
CN110806488B (zh) * 2019-12-06 2020-09-25 南京医科大学 Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用
US20250241906A1 (en) * 2022-02-15 2025-07-31 University Of Central Florida Research Foundation, Inc. Anabolic drugs stimulating type ii collagen production from chondrocytes or their progenitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554500A (en) * 1989-09-27 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Cloned genes for human dopamine D2 receptors and cell lines expressing same
US5427942A (en) * 1991-11-13 1995-06-27 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human D5 dopamine recepltor gene and uses
WO1994022495A1 (fr) * 1993-03-31 1994-10-13 The Trustees Of The University Of Pennsylvania Ligands de recepteurs de la dopamine d-3 et de la serotonine (5-ht1a) et agents d'imagerie
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression

Also Published As

Publication number Publication date
EP1492565A2 (fr) 2005-01-05
WO2003037247A2 (fr) 2003-05-08
AU2002347573A1 (en) 2003-05-12
WO2003037247A3 (fr) 2004-02-26
EP1492565A4 (fr) 2006-04-26
US20050163773A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
EP1465656A4 (fr) Compositions pharmaceutiques et methodes permettant la modulation de l'activite des lymphocytes t par les hormones i et ii de liberation de la gonadotrophine (gnrh-i et gnrh-ii), leur adherence, leur migration et leur extravasation
AU4498400A (en) Nb-ti-zr-mo alloys for medical and dental devices
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2197100A (en) Treatment of tooth surfaces and substance therefor
HUP0400384A3 (en) Benzamidine derivative and pharmaceutical compositions containing them and their use
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU2003267644A1 (en) Dental compositions and methods
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
AU5326100A (en) Pharmaceutical compositions and methods for use
AU4344000A (en) Drug releasing elastic band and method
IL164217A0 (en) Pharmaceutical compositions containing water-soluble propofol and methods of administering same
IL166772A0 (en) Pharmaceuticals formulations and methods for modified release of statin drugs
AU2002329959A1 (en) Stable dental analog systems
IL161003A0 (en) Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity
AU2003296469A1 (en) Dental compositions including enzymes and methods
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002351388A1 (en) Methods and compositions for controlled release of drugs
AU2003271486A1 (en) Intraosseous dental implant and dental implant set
AU2001287198A1 (en) Dental restorative compositions and method of use thereof
AU2003294520A1 (en) Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
AU2003217942A1 (en) Modulators of leukocyte activation, compositions, and methods of use
AU2003295713A1 (en) Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
AU2003256672A8 (en) Modulators of leukocyte activation, bic compositions and methods of use
AU4964200A (en) Prevention of dental caries
IL162564A0 (en) Methods and pharmaceutical compositions for gnrh-iand gnrh-iimodulation of t-cell activity, adhesion, migration and extravasat